Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28663348 | 0.85 | POLB (0.40) | ALDH1A1KMT2AMAPK1POLBTP53 | |
| SCHEMBL17183549 | 0.82 | SMN1; SMN2 (0.36) | ALDH1A1KMT2AMAPK1POLBTP53 | |
| SCHEMBL17183550 | 0.79 | SMN1; SMN2 (0.36) | ALDH1A1TP53AKR1C3LMNASMN1; SMN2 | |
| SCHEMBL17183535 | 0.79 | SMN1; SMN2 (0.39) | ALDH1A1KMT2APOLBCYP2C9CYP2C19 | |
| SCHEMBL8779695 | 0.76 | ALDH1A1 (0.50) | ALDH1A1KMT2AMAPK1POLBTP53 | |
| SCHEMBL23716956 | 0.69 | ALDH1A1 (0.50) | ALDH1A1KMT2AMAPK1POLBTP53 | |
| SCHEMBL11711601 | 0.68 | NPSR1 (0.39) | ALDH1A1KMT2APOLBHPGDSMN1; SMN2 | |
| SCHEMBL10840973 | 0.68 | CHRM4 (0.35) | ALDH1A1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL27899732 | 0.67 | CHRM2 (0.48) | ALDH1A1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL8778553 | 0.67 | HPGD (0.51) | ALDH1A1KMT2ACYP2C19LMNAPHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134088-B1 | BICYLCIC PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES LLC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9718841-B2 | Bicyclic pyrazolone compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170183358-A1 | BICYCLIC PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2017-06-29 | — | — | US | disclosed |
| EP-3134088-A1 | BICYLCIC PYRAZOLONE COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2017-03-01 | — | — | EP | disclosed |
| WO-2015164161-A1 | BICYLCIC PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-10-29 | — | — | WO | disclosed |
| WO-2014170908-A1 | PROCESS FOR PREPARATION OF OXAZOLIDINONE DERIVATIVES | NOSCH LABS PRIVATE LIMITED (IN) | 2014-10-23 | — | — | WO | disclosed |
| US-20140128601-A1 | PROCESS FOR OBTAINING RIVAROXABAN AND INTERMEDIATE THEREOF | INTERQUIM, S.A. (ES) | 2014-05-08 | — | — | US | disclosed |
| EP-2710001-A1 | PROCESS FOR OBTAINING RIVAROXABAN AND INTERMEDIATE THEREOF | Interquim, S.A. (ES) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012159992-A1 | PROCESS FOR OBTAINING RIVAROXABAN AND INTERMEDIATE THEREOF | INTERQUIM, S.A. (ES) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183358-A1 | BICYCLIC PYRAZOLONE COMPOUNDS AND METHODS OF USE | MET, RET, ERBB2 | ALDH1A1 2892/4885KMT2A 2225/4885MAPK1 586/4885 |
| US-20140128601-A1 | PROCESS FOR OBTAINING RIVAROXABAN AND INTERMEDIATE THEREOF | TFPI, CYP2C9, CYP2C19 | ALDH1A1 352/4885KMT2A 863/4885MAPK1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.